Lactosyl-β-cyclodextrin against Hepatomegaly in Niemann-Pick Type C Disease
The first paper in the special issue of Nanomaterials “Nanoconstructs Based on Cyclodextrins” has been published. Mono-lactosyl β-CD (mono-Lac-β-CD) diminished
Tag: Niemann Pick Disease
Novel polyrotaxane for Niemann Pick disease type C treatment
The team of Gerhard Wenz (Saarland University, Germany) has published a novel polyrotaxane: hydroxypropyl-β-cyclodextrin(HPBCD):poly(decamethylenephosphate) which has several advantages over HPBCD
CTD Reports Initial Data for Two Clinical Trials of Trappsol® Cyclo™
CTD Holdings, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical
CTD Announces Partnership with United BioSource
CTD Holdings, a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need,
Cyclodextrin News Year in Review 2018
The CDNews blog was created in July and after a short period of trial it started in September. During this
Cyclodextrins involved in clinical trials to start
According to clinicaltrials.gov, currently, there are 14 cyclodextrin-related clinical trials that in the status of i) Not yet recruiting, ii)
HPBCD treatment for Niemann-Pick C: Mallinckrodt communicated results of clinical trial
Mallinckrodt Pharmaceuticals recently revealed findings of their completed registration trial for VTS-270 (Hydroxypropyl Betadex- HPBCD), a development product to treat
Therapeutic potential for cyclodextrin‐based macromolecular systems in NPC
A paper has just come out in Macromolecular Rapid Communications highlighting the potential benefits of cyclodextrin-based macromolecular systems as cholesterol-mopping
HPBCD was tested for revealing the symptoms of Cockayne syndrome in mouse model: a surprise
Cockayne syndrome is a hereditary form of premature aging caused by a gene mutation. The disease affects more organs including
Different cyclodextrins to treat NPC
If you are following advances in the re-discovery of cyclodextrins as APIs, there is quite a race among the candidates